======= PFKP ======= == Gene Information == * **Official Symbol**: PFKP * **Official Name**: phosphofructokinase, platelet * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=5214|5214]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q01813|Q01813]] * **Interactions**: [[https://thebiogrid.org/search.php?search=PFKP&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PFKP|Open PubMed]] * **OMIM**: [[https://omim.org/entry/171840|Open OMIM]] == Function Summary == * **Entrez Summary**: This gene encodes a member of the phosphofructokinase A protein family. The encoded enzyme is the platelet-specific isoform of phosphofructokinase and plays a key role in glycolysis regulation. This gene may play a role in metabolic reprogramming in some cancers, including clear cell renal cell carcinomas, and cancer of the bladder, breast, and lung. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016]. * **UniProt Summary**: Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis. |PFK| |6-phosphofructokinase complex| |6-phosphofructokinase activity| |fructose-6-phosphate binding| |fructose 6-phosphate metabolic process| |fructose 1,6-bisphosphate metabolic process| |AMP binding| |monosaccharide binding| |NADH regeneration| |glucose catabolic process to pyruvate| |canonical glycolysis| |glycolytic process through glucose-6-phosphate| |glycolytic process through fructose-6-phosphate| |glucose catabolic process| |NADH metabolic process| |glycolytic process| |ATP generation from ADP| |NAD metabolic process| |ADP metabolic process| |hexose catabolic process| |nucleoside diphosphate phosphorylation| |purine ribonucleoside diphosphate metabolic process| |nucleotide phosphorylation| |purine nucleoside diphosphate metabolic process| |monosaccharide catabolic process| |ribonucleoside diphosphate metabolic process| |pyruvate metabolic process| |nucleoside diphosphate metabolic process| |protein homotetramerization| |response to leukemia inhibitory factor| |cellular response to leukemia inhibitory factor| |glucose metabolic process| |carbohydrate catabolic process| |protein tetramerization| |hexose metabolic process| |monosaccharide metabolic process| |ATP metabolic process| |protein-containing complex binding| |cadherin binding| |purine ribonucleotide metabolic process| |ribonucleotide metabolic process| |purine nucleotide metabolic process| |ribose phosphate metabolic process| |protein homooligomerization| |purine-containing compound metabolic process| |generation of precursor metabolites and energy| |small molecule catabolic process| |nucleotide metabolic process| |nucleoside phosphate metabolic process| |carbohydrate metabolic process| |protein complex oligomerization| |monocarboxylic acid metabolic process| |nucleobase-containing small molecule metabolic process| |organophosphate metabolic process| |carboxylic acid metabolic process| |oxidation-reduction process| |oxoacid metabolic process| |cellular response to cytokine stimulus| |organic acid metabolic process| |carbohydrate derivative metabolic process| |identical protein binding| |response to cytokine| |phosphorylation| |ATP binding| |protein-containing complex assembly| |small molecule metabolic process| |organic substance catabolic process| |protein-containing complex subunit organization| |membrane| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp439|QNZ 0.01μM R08 exp439]]|-3| |[[:results:exp25|Oligomycin-A 2μM R00 exp25]]|-2.25| |[[:results:exp431|Rotenone 0.07μM R08 exp431]]|-2.23| |[[:results:exp34|Rotenone 20μM R00 exp34]]|-2.05| |[[:results:exp191|Hypoxia 5%O2 R04 exp191]]|-1.97| |[[:results:exp210|LB-100 2μM R05 exp210]]|1.76| |[[:results:exp499|LY2090314 0.003μM R08 exp499]]|1.76| |[[:results:exp270|Campthothecin 0.001μM R06 exp270]]|1.78| |[[:results:exp334|All-trans-Retinoic-Acid 40μM R07 exp334]]|1.8| |[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|1.8| |[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|1.8| |[[:results:exp264|Arsenate 40μM R06 exp264]]|1.86| |[[:results:exp415|Trichostatin-A 0.06μM R07 exp415]]|1.86| |[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|1.87| |[[:results:exp312|2-Methoxyestradiol 0.55 to 1μM on day4 R07 exp312]]|1.88| |[[:results:exp247|UM0130462 0.025 to 0.035μM day4 R05 exp247]]|1.88| |[[:results:exp510|Nicotine 3000μM R08 exp510]]|1.89| |[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|1.9| |[[:results:exp319|ABT-702 5μM plus Dimethyloxaloylglycine 11μM R07 exp319]]|1.92| |[[:results:exp355|Dinaciclib 0.007μM R07 exp355]]|1.94| |[[:results:exp517|Quercetin 20μM R08 exp517]]|1.97| |[[:results:exp512|Olaparib 4μM R08 exp512]]|2.04| |[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|2.07| |[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|2.09| |[[:results:exp81|Selumetinib 20μM R02 exp81]]|2.12| |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|2.18| |[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|2.23| |[[:results:exp103|Taxol 0.004μM R03 exp103]]|2.24| |[[:results:exp461|BS-181 20μM R08 exp461]]|2.3| |[[:results:exp416|Tubacin 1.6μM R07 exp416]]|2.32| |[[:results:exp75|MK-1775 0.32μM R02 exp75]]|2.35| |[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|2.41| |[[:results:exp216|Erlotinib 10μM R05 exp216]]|2.42| |[[:results:exp356|Docosahexaenoic-acid 50μM R07 exp356]]|2.48| |[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|2.56| |[[:results:exp175|3-Bromopyruvate 7μM R04 exp175]]|2.61| |[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|2.85| |[[:results:exp84|UM0125461 0.74μM R02 exp84]]|3.11| |[[:results:exp79|Q15 2.7μM R02 exp79]]|3.39| |[[:results:exp214|2-Deoxy-D-glucose 800μM R05 exp214]]|7.65| ^Gene^Correlation^ |[[:human genes:h:hk2|HK2]]|0.709| |[[:human genes:h:hk1|HK1]]|0.6| |[[:human genes:s:slc2a1|SLC2A1]]|0.599| |[[:human genes:g:gpi|GPI]]|0.512| |[[:human genes:p:pgp|PGP]]|0.512| |[[:human genes:m:mlf2|MLF2]]|0.479| |[[:human genes:p:pgls|PGLS]]|0.461| |[[:human genes:a:ahcyl1|AHCYL1]]|0.454| |[[:human genes:g:got1|GOT1]]|0.439| |[[:human genes:s:slc16a1|SLC16A1]]|0.428| |[[:human genes:v:vdac1|VDAC1]]|0.422| |[[:human genes:s:snx27|SNX27]]|0.408| Global Fraction of Cell Lines Where Essential: 1/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|1/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 674 * **Expression level (log2 read counts)**: 7.3 {{:chemogenomics:nalm6 dist.png?nolink |}}